Investment Thesis
ANIP demonstrates strong operational efficiency with 12.6% operating margin and exceptional free cash flow generation ($171.4M, 19.4% FCF margin), indicating sustainable profitability despite the company's pharmaceutical sector challenges. However, the extraordinary 6965.8% revenue growth warrants investigation into acquisition activity or one-time gains rather than organic scaling, while elevated insider trading activity (42 Form 4 filings) suggests potential insider concerns about valuation or strategy.
ANIP Strengths
- Robust free cash flow of $171.4M with 19.4% FCF margin demonstrates strong cash generation capability
- Healthy liquidity position with 2.71x current ratio and $285.6M cash on hand
- Solid operating margin of 12.6% and net margin of 8.9% indicate operational efficiency and profitability
- Conservative leverage with 0.54x debt-to-equity ratio and 3.4x interest coverage ratio
- Strong return on equity of 14.5% showing effective capital deployment
ANIP Risks
- Extraordinary revenue growth of 6965.8% is atypical and likely driven by acquisition/one-time event rather than organic growth—sustainability is highly questionable
- Unusually high insider Form 4 filings (42 in 90 days) may indicate insider concern about company direction or valuation
- Missing gross margin data prevents assessment of pricing power, manufacturing efficiency, and product mix quality
- Net income growth of only 1.5% YoY despite massive revenue growth suggests operational margin compression or unusual charges
- Long-term debt of $291.8M represents 54% of equity and may constrain financial flexibility for R&D or strategic investments
Key Metrics to Watch
- Organic revenue growth rate and contribution of acquisitions to current period revenue
- Gross margin trends and product-level profitability to assess pricing sustainability
- Insider transaction volume and direction—significant selling would raise additional concerns
- Free cash flow sustainability and capital allocation priorities (debt reduction vs. R&D investment)
- Operating margin trajectory as any integration costs or one-time benefits normalize
ANIP Financial Metrics
ANIP Profitability Ratios
ANIP Balance Sheet & Liquidity
ANIP 5-Year Financial Trend
5-Year Trend Summary: ANI PHARMACEUTICALS INC's revenue has grown significantly by 309% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.85 reflects profitable operations.
ANIP Growth Metrics (YoY)
ANIP Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $148.3M | -$8.2M | $-0.49 |
| Q2 2025 | $138.0M | -$2.3M | $-0.14 |
| Q1 2025 | $137.4M | $15.7M | $0.69 |
| Q3 2024 | $131.8M | -$8.2M | $0.45 |
| Q2 2024 | $116.5M | -$2.3M | $-0.14 |
| Q1 2024 | $106.8M | $1.4M | $0.06 |
| Q3 2023 | $83.8M | -$8.6M | $0.45 |
| Q2 2023 | $73.9M | $6.2M | $0.29 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ANIP Capital Allocation
ANIP SEC Filings
Access official SEC EDGAR filings for ANI PHARMACEUTICALS INC (CIK: 0001023024)